{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:18:05Z","timestamp":1770329885510,"version":"3.49.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11864-025-01297-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T10:09:16Z","timestamp":1743761356000},"page":"313-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5766-4894","authenticated-orcid":false,"given":"Shijia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-0840","authenticated-orcid":false,"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"20","key":"1297_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"3","key":"1297_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/leu.2014.251","volume":"29","author":"HR Junl\u00e9n","year":"2015","unstructured":"Junl\u00e9n HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668\u201376. https:\/\/doi.org\/10.1038\/leu.2014.251.","journal-title":"Leukemia"},{"issue":"11","key":"1297_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229\u201353. https:\/\/doi.org\/10.1182\/blood.2022015851.","journal-title":"Blood"},{"issue":"6","key":"1297_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2014.04.008","volume":"14","author":"G Vaidyanathan","year":"2014","unstructured":"Vaidyanathan G. Czuczman MS Follicular lymphoma grade 3: review and updates. Clin Lymphoma Myeloma Leuk. 2014;14(6):431\u20135. https:\/\/doi.org\/10.1016\/j.clml.2014.04.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1297_CR5","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. (2022) Correction: \"The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms\" Leukemia. 36(7):1720\u20131748[J].Leukemia 2023;37(9):1944\u20131951. https:\/\/doi.org\/10.1038\/s41375-023-01962-5","DOI":"10.1038\/s41375-023-01962-5"},{"issue":"19","key":"1297_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/nejm198711053171904","volume":"317","author":"LM Weiss","year":"1987","unstructured":"Weiss LM, Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317(19):1185\u20139. https:\/\/doi.org\/10.1056\/nejm198711053171904.","journal-title":"N Engl J Med"},{"issue":"2","key":"1297_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176\u201381. https:\/\/doi.org\/10.1038\/ng.2856.","journal-title":"Nat Genet"},{"issue":"7337","key":"1297_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189\u201395. https:\/\/doi.org\/10.1038\/nature09730.","journal-title":"Nature"},{"issue":"7360","key":"1297_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298\u2013303. https:\/\/doi.org\/10.1038\/nature10351.","journal-title":"Nature"},{"issue":"10","key":"1297_CR10","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","volume":"112","author":"MR Green","year":"2015","unstructured":"Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015;112(10):E1116-1125. https:\/\/doi.org\/10.1073\/pnas.1501199112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1297_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2159-8290.Cd-16-1417","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Vlasevska S, Wells VA, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov. 2017;7(3):322\u201337. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-1417.","journal-title":"Cancer Discov"},{"issue":"10","key":"1297_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"A Ortega-Molina","year":"2015","unstructured":"Ortega-Molina A, Boss IW, Canela A, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21(10):1199\u2013208. https:\/\/doi.org\/10.1038\/nm.3943.","journal-title":"Nat Med"},{"issue":"5","key":"1297_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.Bcd-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han G, Deng Q, Marques-Piubelli ML, et al. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022;3(5):428\u201343. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0075.","journal-title":"Blood Cancer Discov"},{"issue":"21","key":"1297_CR14","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369. https:\/\/doi.org\/10.1056\/NEJMoa041869.","journal-title":"N Engl J Med"},{"issue":"12","key":"1297_CR15","doi-asserted-by":"publisher","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel R, Chan FC, Mottok A, et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med. 2016;13(12):e1002197. https:\/\/doi.org\/10.1371\/journal.pmed.1002197.","journal-title":"PLoS Med"},{"issue":"23","key":"1297_CR16","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1200\/jco.2018.79.3083","volume":"36","author":"JW Friedberg","year":"2018","unstructured":"Friedberg JW. Progress in Advanced-Stage Follicular Lymphoma. J Clin Oncol. 2018;36(23):2363\u20135. https:\/\/doi.org\/10.1200\/jco.2018.79.3083.","journal-title":"J Clin Oncol"},{"key":"1297_CR17","doi-asserted-by":"publisher","unstructured":"Shadman M, Li H, Rimsza L, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016[J] .J Clin Oncol 2018;36(7):697\u2013703. https:\/\/doi.org\/10.1200\/jco.2017.74.5083","DOI":"10.1200\/jco.2017.74.5083"},{"issue":"4","key":"1297_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.15149","volume":"184","author":"BK Link","year":"2019","unstructured":"Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660\u20133. https:\/\/doi.org\/10.1111\/bjh.15149.","journal-title":"Br J Haematol"},{"issue":"4","key":"1297_CR19","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/s2352-3026(22)00033-3","volume":"9","author":"C Casulo","year":"2022","unstructured":"Casulo C, Larson MC, Lunde JJ, et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022;9(4):e289\u2013300. https:\/\/doi.org\/10.1016\/s2352-3026(22)00033-3.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1297_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981\u20137. https:\/\/doi.org\/10.1182\/blood-2013-03-491514.","journal-title":"Blood"},{"issue":"5","key":"1297_CR21","doi-asserted-by":"publisher","first-page":"e0177204","DOI":"10.1371\/journal.pone.0177204","volume":"12","author":"M Provencio","year":"2017","unstructured":"Provencio M, Sab\u00edn P, Gomez-Codina J, et al. Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. PLoS One. 2017;12(5):e0177204. https:\/\/doi.org\/10.1371\/journal.pone.0177204.","journal-title":"PLoS One"},{"issue":"2","key":"1297_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/jco.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, et al. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2019;37(2):144\u201352. https:\/\/doi.org\/10.1200\/jco.18.00400.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1297_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","volume":"7","author":"P Soubeyran","year":"1996","unstructured":"Soubeyran P, Eghbali H, Trojani M, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7(7):713\u20138. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010720.","journal-title":"Ann Oncol"},{"issue":"3","key":"1297_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","volume":"64","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1\u20132 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.08.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1297_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1297_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/s1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457\u201363. https:\/\/doi.org\/10.1016\/s1470-2045(14)70036-1.","journal-title":"Lancet Oncol"},{"issue":"29","key":"1297_CR27","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/jco.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus M, Fisher R, Roos D, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918\u201325. https:\/\/doi.org\/10.1200\/jco.2018.77.9892.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1297_CR28","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/jco.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997;15(3):1110\u20137. https:\/\/doi.org\/10.1200\/jco.1997.15.3.1110.","journal-title":"J Clin Oncol"},{"issue":"9383","key":"1297_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(03)14110-4.","journal-title":"Lancet"},{"issue":"31","key":"1297_CR30","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/jco.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848\u201353. https:\/\/doi.org\/10.1200\/jco.2010.33.4474.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1297_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/s1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(14)70027-0.","journal-title":"Lancet Oncol"},{"issue":"28","key":"1297_CR32","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1200\/jco.2014.56.5853","volume":"32","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096\u2013102. https:\/\/doi.org\/10.1200\/jco.2014.56.5853.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1297_CR33","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/jco.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579\u201386. https:\/\/doi.org\/10.1200\/jco.2007.13.5376.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1297_CR34","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Blood. 2005;106(12):3725\u201332. https:\/\/doi.org\/10.1182\/blood-2005-01-0016.","journal-title":"Blood"},{"issue":"15","key":"1297_CR35","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/jco.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986\u201392. https:\/\/doi.org\/10.1200\/jco.2006.06.4618.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1297_CR36","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","volume":"98","author":"E Bachy","year":"2013","unstructured":"Bachy E, Houot R, Morschhauser F, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013;98(7):1107\u201314. https:\/\/doi.org\/10.3324\/haematol.2012.082412.","journal-title":"Haematologica"},{"key":"1297_CR37","doi-asserted-by":"publisher","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H, et al. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. J Clin Oncol 2018;Jco1800262. https:\/\/doi.org\/10.1200\/jco.18.00262","DOI":"10.1200\/jco.18.00262"},{"issue":"23","key":"1297_CR38","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/jco.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018;36(23):2395\u2013404. https:\/\/doi.org\/10.1200\/jco.2017.76.8960.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1297_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/jco.23.00838","volume":"42","author":"C Pott","year":"2024","unstructured":"Pott C, Jurinovic V, Trotman J, et al. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. J Clin Oncol. 2024;42(5):550\u201361. https:\/\/doi.org\/10.1200\/jco.23.00838.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1297_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/jco.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019;37(12):984\u201391. https:\/\/doi.org\/10.1200\/jco.18.00605.","journal-title":"J Clin Oncol"},{"issue":"9873","key":"1297_CR41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(12)61763-2.","journal-title":"Lancet"},{"issue":"1","key":"1297_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.15513","volume":"183","author":"E Gyan","year":"2018","unstructured":"Gyan E, Sonet A, Brice P, et al. Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. Br J Haematol. 2018;183(1):76\u201386. https:\/\/doi.org\/10.1111\/bjh.15513.","journal-title":"Br J Haematol"},{"key":"1297_CR43","doi-asserted-by":"publisher","unstructured":"Mondello P, Strati P, Merryman RW, et al. R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET[J].Blood 2020;136(Supplement 1):39\u201340. https:\/\/doi.org\/10.1182\/blood-2020-136438 %J Blood","DOI":"10.1182\/blood-2020-136438"},{"issue":"7","key":"1297_CR44","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","volume":"105","author":"P Strati","year":"2020","unstructured":"Strati P, Ahmed MA, Fowler NH, et al. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020;105(7):1907\u201313. https:\/\/doi.org\/10.3324\/haematol.2019.230649.","journal-title":"Haematologica"},{"issue":"1","key":"1297_CR45","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-022-10070-z","volume":"22","author":"C Mart\u00ednez-Laperche","year":"2022","unstructured":"Mart\u00ednez-Laperche C, Sanz-Villanueva L, D\u00edaz Crespo FJ, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22(1):982. https:\/\/doi.org\/10.1186\/s12885-022-10070-z.","journal-title":"BMC Cancer"},{"issue":"25","key":"1297_CR46","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/jco.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N. Morschhauser F Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2015;33(25):2803\u201311. https:\/\/doi.org\/10.1200\/jco.2014.59.5363.","journal-title":"J Clin Oncol"},{"key":"1297_CR47","doi-asserted-by":"publisher","unstructured":"Martin P, Jung SH, Pitcher B, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)[J].Ann Oncol 2017;28(11):2806\u20132812. https:\/\/doi.org\/10.1093\/annonc\/mdx496","DOI":"10.1093\/annonc\/mdx496"},{"issue":"10","key":"1297_CR48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018;379(10):934\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1805104.","journal-title":"N Engl J Med"},{"issue":"28","key":"1297_CR49","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/jco.22.00843","volume":"40","author":"F Morschhauser","year":"2022","unstructured":"Morschhauser F, Nastoupil L, Feugier P, et al. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022;40(28):3239\u201345. https:\/\/doi.org\/10.1200\/jco.22.00843.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1297_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","volume":"134","author":"E Zucca","year":"2019","unstructured":"Zucca E, Rondeau S, Vanazzi A, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. 2019;134(4):353\u201362. https:\/\/doi.org\/10.1182\/blood-2018-10-879643.","journal-title":"Blood"},{"issue":"15","key":"1297_CR51","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood.2021013526","volume":"139","author":"E Bachy","year":"2022","unstructured":"Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 2022;139(15):2338\u201346. https:\/\/doi.org\/10.1182\/blood.2021013526.","journal-title":"Blood"},{"key":"1297_CR52","doi-asserted-by":"publisher","unstructured":"Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis[J].J Natl Cancer Inst 2012;104(1):18\u201328. https:\/\/doi.org\/10.1093\/jnci\/djr450","DOI":"10.1093\/jnci\/djr450"},{"issue":"9759","key":"1297_CR53","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(10)62175-7.","journal-title":"Lancet"},{"issue":"4","key":"1297_CR54","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bjh.15720","volume":"184","author":"BT Hill","year":"2019","unstructured":"Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184(4):524\u201335. https:\/\/doi.org\/10.1111\/bjh.15720.","journal-title":"Br J Haematol"},{"issue":"7","key":"1297_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/jco.21.01234","volume":"40","author":"S Luminari","year":"2022","unstructured":"Luminari S, Manni M, Galimberti S, et al. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol. 2022;40(7):729\u201339. https:\/\/doi.org\/10.1200\/jco.21.01234.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1297_CR56","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/cam4.1622","volume":"7","author":"HH Huang","year":"2018","unstructured":"Huang HH, Wen YC, Chen HM, et al. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database. Cancer Med. 2018;7(8):3582\u201391. https:\/\/doi.org\/10.1002\/cam4.1622.","journal-title":"Cancer Med"},{"issue":"23","key":"1297_CR57","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/jco.2014.59.7534.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1297_CR58","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/jco.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(32):5165\u20139. https:\/\/doi.org\/10.1200\/jco.2008.16.0283.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1297_CR59","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851\u20137. https:\/\/doi.org\/10.1182\/blood-2015-01-621375.","journal-title":"Blood"},{"issue":"23","key":"1297_CR60","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1200\/jco.2012.46.9718","volume":"31","author":"GA Salles","year":"2013","unstructured":"Salles GA, Morschhauser F, Solal-C\u00e9ligny P, et al. Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920\u20136. https:\/\/doi.org\/10.1200\/jco.2012.46.9718.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1297_CR61","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137\u201343. https:\/\/doi.org\/10.1182\/blood-2013-01-481341.","journal-title":"Blood"},{"issue":"31","key":"1297_CR62","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/jco.2014.59.9258","volume":"33","author":"JP Leonard","year":"2015","unstructured":"Leonard JP, Jung SH, Johnson J, et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635\u201340. https:\/\/doi.org\/10.1200\/jco.2014.59.9258.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1297_CR63","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/jco.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019;37(14):1188\u201399. https:\/\/doi.org\/10.1200\/jco.19.00010.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1297_CR64","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/s2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study\\. Lancet Haematol. 2019;6(8):e429\u201337. https:\/\/doi.org\/10.1016\/s2352-3026(19)30089-4.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1297_CR65","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med"},{"issue":"11","key":"1297_CR66","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/jco.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019;37(11):912\u201322. https:\/\/doi.org\/10.1200\/jco.18.00915.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1297_CR67","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/jco.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017;35(35):3898\u2013905. https:\/\/doi.org\/10.1200\/jco.2017.75.4648.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1297_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362\u201371. https:\/\/doi.org\/10.1002\/ajh.25711.","journal-title":"Am J Hematol"},{"issue":"3","key":"1297_CR69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","volume":"16","author":"J Munoz","year":"2021","unstructured":"Munoz J, Follows GA. Nastoupil LJ Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Target Oncol. 2021;16(3):295\u2013308. https:\/\/doi.org\/10.1007\/s11523-021-00802-9.","journal-title":"Target Oncol"},{"issue":"5","key":"1297_CR70","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/s1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678\u201389. https:\/\/doi.org\/10.1016\/s1470-2045(21)00145-5.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1297_CR71","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia E. Salles G EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 2021;17(17):2127\u201340. https:\/\/doi.org\/10.2217\/fon-2020-1244.","journal-title":"Future Oncol"},{"issue":"11","key":"1297_CR72","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/s1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30441-1.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1297_CR73","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/jco.2010.32.1398","volume":"29","author":"M Kirschbaum","year":"2011","unstructured":"Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198\u2013203. https:\/\/doi.org\/10.1200\/jco.2010.32.1398.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1297_CR74","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.Ccr-15-0624","volume":"22","author":"AM Evens","year":"2016","unstructured":"Evens AM, Balasubramanian S, Vose JM, et al. A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma. Clin Cancer Res. 2016;22(5):1059\u201366. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0624.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1297_CR75","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/jco.2017.76.8853","volume":"36","author":"AK Gopal","year":"2018","unstructured":"Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for Patients With Relapsed\/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018;36(23):2405\u201312. https:\/\/doi.org\/10.1200\/jco.2017.76.8853.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1297_CR76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","volume":"131","author":"NL Bartlett","year":"2018","unstructured":"Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182\u201390. https:\/\/doi.org\/10.1182\/blood-2017-09-804641.","journal-title":"Blood"},{"issue":"1","key":"1297_CR77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","volume":"13","author":"CS Tam","year":"2023","unstructured":"Tam CS, Mu\u00f1oz JL, Seymour JF, et al. Zanubrutinib: past, present, and future. Blood Cancer J. 2023;13(1):141. https:\/\/doi.org\/10.1038\/s41408-023-00902-x.","journal-title":"Blood Cancer J"},{"key":"1297_CR78","doi-asserted-by":"publisher","first-page":"204062072210939","DOI":"10.1177\/20406207221093980","volume":"13","author":"J Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz J, Wang Y, Jain P, et al. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Ther Adv Hematol. 2022;13:20406207221093980. https:\/\/doi.org\/10.1177\/20406207221093980.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"1297_CR79","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","volume":"6","author":"CS Tam","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296\u2013308. https:\/\/doi.org\/10.1182\/bloodadvances.2021005621.","journal-title":"Blood Adv"},{"issue":"1","key":"1297_CR80","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40164-024-00551-1","volume":"13","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Mu\u00f1oz J. Trotman J Current and future therapies for follicular lymphoma. Exp Hematol Oncol. 2024;13(1):87. https:\/\/doi.org\/10.1186\/s40164-024-00551-1.","journal-title":"Exp Hematol Oncol"},{"issue":"33","key":"1297_CR81","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/jco.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol. 2023;41(33):5107\u201317. https:\/\/doi.org\/10.1200\/jco.23.00775.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1297_CR82","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964\u201376. https:\/\/doi.org\/10.1182\/blood-2018-11-880526.","journal-title":"Blood"},{"issue":"9","key":"1297_CR83","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","volume":"29","author":"S de Vos","year":"2018","unstructured":"de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy256.","journal-title":"Ann Oncol"},{"issue":"6","key":"1297_CR84","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243.","journal-title":"Blood"},{"issue":"2","key":"1297_CR85","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0.","journal-title":"Nat Med"},{"issue":"5","key":"1297_CR86","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254\u201365. https:\/\/doi.org\/10.1016\/s2352-3026(19)30026-2.","journal-title":"Lancet Haematol"},{"issue":"12","key":"1297_CR87","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1016\/s2352-3026(21)00311-2","volume":"8","author":"C Diefenbach","year":"2021","unstructured":"Diefenbach C, Kahl BS, McMillan A, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study. Lancet Haematol. 2021;8(12):e891\u2013901. https:\/\/doi.org\/10.1016\/s2352-3026(21)00311-2.","journal-title":"Lancet Haematol"},{"issue":"19","key":"1297_CR88","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345. https:\/\/doi.org\/10.1182\/blood.2020007512.","journal-title":"Blood"},{"issue":"5","key":"1297_CR89","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/jco.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573\u201383. https:\/\/doi.org\/10.1200\/jco.2012.42.7211.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1297_CR90","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(22)00335-7.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1297_CR91","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/s2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593\u2013605. https:\/\/doi.org\/10.1016\/s2352-3026(24)00166-2.","journal-title":"Lancet Haematol"},{"issue":"18","key":"1297_CR92","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/jco.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959\u201370. https:\/\/doi.org\/10.1200\/jco.20.03175.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1297_CR93","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.2019004753","volume":"137","author":"P Armand","year":"2021","unstructured":"Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma. Blood. 2021;137(5):637\u201345. https:\/\/doi.org\/10.1182\/blood.2019004753.","journal-title":"Blood"},{"issue":"2","key":"1297_CR94","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/s2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378. https:\/\/doi.org\/10.1016\/s2352-3026(18)30217-5.","journal-title":"Lancet Haematol"},{"issue":"18","key":"1297_CR95","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma. N Engl J Med. 2018;379(18):1711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1807315.","journal-title":"N Engl J Med"},{"key":"1297_CR96","doi-asserted-by":"publisher","unstructured":"Manna M, Lee-Ying R, Davies G, et al. (2019) Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma;60(1):133\u2013141. https:\/\/doi.org\/10.1080\/10428194.2018.1473576","DOI":"10.1080\/10428194.2018.1473576"},{"issue":"10","key":"1297_CR97","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521\u20139. https:\/\/doi.org\/10.1182\/blood-2003-04-1205.","journal-title":"Blood"},{"issue":"8","key":"1297_CR98","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang MJ, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733\u201342. https:\/\/doi.org\/10.1002\/cncr.31264.","journal-title":"Cancer"},{"key":"1297_CR99","doi-asserted-by":"publisher","unstructured":"A predictive model for aggressive non-Hodgkin's lymphoma[J].N Engl J Med 1993;329(14):987\u2013994. https:\/\/doi.org\/10.1056\/nejm199309303291402","DOI":"10.1056\/nejm199309303291402"},{"issue":"5","key":"1297_CR100","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434.","journal-title":"Blood"},{"issue":"2","key":"1297_CR101","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Nabhan C, Zhou X, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013;24(2):441\u20138. https:\/\/doi.org\/10.1093\/annonc\/mds429.","journal-title":"Ann Oncol"},{"issue":"27","key":"1297_CR102","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/jco.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362. https:\/\/doi.org\/10.1200\/jco.2008.21.3991.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1297_CR103","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1200\/jco.2008.17.0910","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805\u201311. https:\/\/doi.org\/10.1200\/jco.2008.17.0910.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1297_CR104","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/s1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(15)00169-2.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1297_CR105","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, Ren W, Brodtkorb M, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259\u201367. https:\/\/doi.org\/10.1111\/bjh.16159.","journal-title":"Br J Haematol"},{"issue":"1","key":"1297_CR106","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405.","journal-title":"Blood"},{"issue":"17","key":"1297_CR107","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS. Yang DT Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055\u201363. https:\/\/doi.org\/10.1182\/blood-2015-11-624288.","journal-title":"Blood"},{"issue":"2","key":"1297_CR108","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","volume":"156","author":"BE Wahlin","year":"2012","unstructured":"Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156(2):225\u201333. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08942.x.","journal-title":"Br J Haematol"},{"issue":"9","key":"1297_CR109","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3324\/haematol.2023.282893","volume":"108","author":"E Mulvey","year":"2023","unstructured":"Mulvey E. Leonard JP Follicular lymphoma grade 3B: low grade, high grade or should we skip the grade? Haematologica. 2023;108(9):2267\u20138. https:\/\/doi.org\/10.3324\/haematol.2023.282893.","journal-title":"Haematologica"},{"issue":"7","key":"1297_CR110","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","volume":"27","author":"K Koch","year":"2016","unstructured":"Koch K, Hoster E, Ziepert M, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27(7):1323\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw185.","journal-title":"Ann Oncol"},{"issue":"7","key":"1297_CR111","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3324\/haematol.2017.181024","volume":"103","author":"H Horn","year":"2018","unstructured":"Horn H, Kohler C, Witzig R, et al. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. Haematologica. 2018;103(7):1182\u201390. https:\/\/doi.org\/10.3324\/haematol.2017.181024.","journal-title":"Haematologica"},{"issue":"17","key":"1297_CR112","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1200\/jco.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426\u201333. https:\/\/doi.org\/10.1200\/jco.2006.09.3260.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1297_CR113","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/s2352-3026(18)30090-5","volume":"5","author":"M Federico","year":"2018","unstructured":"Federico M, Caballero Barrig\u00f3n MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):e359\u201367. https:\/\/doi.org\/10.1016\/s2352-3026(18)30090-5.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1297_CR114","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.2601","volume":"37","author":"M M\u00e9ndez","year":"2019","unstructured":"M\u00e9ndez M, Torrente M, S\u00e1nchez-Beato M, et al. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019;37(2):143\u201350. https:\/\/doi.org\/10.1002\/hon.2601.","journal-title":"Hematol Oncol"},{"issue":"9","key":"1297_CR115","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761\u20134. https:\/\/doi.org\/10.1182\/blood.2019000258.","journal-title":"Blood"},{"key":"1297_CR116","doi-asserted-by":"publisher","unstructured":"Rusconi C, Anastasia A, Chiarenza A, et al. Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). Br J Haematol 2019;185(4):713\u2013717. https:\/\/doi.org\/10.1111\/bjh.15816","DOI":"10.1111\/bjh.15816"},{"key":"1297_CR117","doi-asserted-by":"publisher","unstructured":"Gleeson M, Hawkes EA, Peckitt C, et al. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003\u20132013. Leuk Lymphoma 2017;58(8):1805\u20131813. https:\/\/doi.org\/10.1080\/10428194.2016.1265114","DOI":"10.1080\/10428194.2016.1265114"},{"issue":"2","key":"1297_CR118","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/annonc\/mdu537","volume":"26","author":"C Madsen","year":"2015","unstructured":"Madsen C, Pedersen MB, Vase M, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. Ann Oncol. 2015;26(2):393\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdu537.","journal-title":"Ann Oncol"},{"issue":"9","key":"1297_CR119","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/jco.2012.44.0693","volume":"31","author":"D Villa","year":"2013","unstructured":"Villa D, Crump M, Panzarella T, et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol. 2013;31(9):1164\u201371. https:\/\/doi.org\/10.1200\/jco.2012.44.0693.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1297_CR120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;5(1):83. https:\/\/doi.org\/10.1038\/s41572-019-0132-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1297_CR121","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684\u201393. https:\/\/doi.org\/10.1182\/blood.2020010263.","journal-title":"Blood"},{"issue":"8","key":"1297_CR122","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112\u201320. https:\/\/doi.org\/10.1182\/blood-2016-05-717355.","journal-title":"Blood"},{"issue":"2","key":"1297_CR123","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdt562.","journal-title":"Ann Oncol"},{"issue":"35","key":"1297_CR124","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/jco.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317\u201322. https:\/\/doi.org\/10.1200\/jco.2012.43.0934.","journal-title":"J Clin Oncol"},{"key":"1297_CR125","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy (18)F-FDG PET\/CT in patients with follicular lymphoma. Cancer Manag Res 2019;11(6871\u20136885. https:\/\/doi.org\/10.2147\/cmar.S216445","DOI":"10.2147\/cmar.S216445"},{"key":"1297_CR126","doi-asserted-by":"publisher","unstructured":"Cottereau AS, Versari A, Luminari S, et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study. Blood 2018;131(22):2449\u20132453. https:\/\/doi.org\/10.1182\/blood-2017-11-816298","DOI":"10.1182\/blood-2017-11-816298"},{"key":"1297_CR127","doi-asserted-by":"publisher","unstructured":"Liang JH, Zhang YP, Xia J, et al. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. Cancer Res Treat 2019;51(4):1479\u20131487. https:\/\/doi.org\/10.4143\/crt.2018.649","DOI":"10.4143\/crt.2018.649"},{"issue":"30","key":"1297_CR128","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/jco.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. J Clin Oncol. 2016;34(30):3618\u201326. https:\/\/doi.org\/10.1200\/jco.2016.66.9440.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1297_CR129","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3324\/haematol.2019.220160","volume":"105","author":"W Townsend","year":"2020","unstructured":"Townsend W, Pasikowska M, Yallop D, et al. The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. Haematologica. 2020;105(6):1593\u2013603. https:\/\/doi.org\/10.3324\/haematol.2019.220160.","journal-title":"Haematologica"},{"issue":"1","key":"1297_CR130","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-023-00899-3","volume":"13","author":"ZZ Yang","year":"2023","unstructured":"Yang ZZ, Kim HJ, Wu H, et al. T-cell phenotype including CD57(+) T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma. Blood Cancer J. 2023;13(1):124. https:\/\/doi.org\/10.1038\/s41408-023-00899-3.","journal-title":"Blood Cancer J"},{"issue":"18","key":"1297_CR131","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2016-08-737239","volume":"129","author":"S Pandey","year":"2017","unstructured":"Pandey S, Mourcin F, Marchand T, et al. IL-4\/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood. 2017;129(18):2507\u201318. https:\/\/doi.org\/10.1182\/blood-2016-08-737239.","journal-title":"Blood"},{"issue":"20","key":"1297_CR132","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1182\/bloodadvances.2021005722","volume":"5","author":"S Gouni","year":"2021","unstructured":"Gouni S, Marques-Piubelli ML. Strati P Follicular lymphoma and macrophages: impact of approved and novel therapies. Blood Adv. 2021;5(20):4303\u201312. https:\/\/doi.org\/10.1182\/bloodadvances.2021005722.","journal-title":"Blood Adv"},{"issue":"1","key":"1297_CR133","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","volume":"133","author":"X Qu","year":"2019","unstructured":"Qu X, Li H, Braziel RM, et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2019;133(1):81\u201393. https:\/\/doi.org\/10.1182\/blood-2018-07-865428.","journal-title":"Blood"},{"issue":"4","key":"1297_CR134","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1101\/gad.275453.115","volume":"30","author":"T Kantidakis","year":"2016","unstructured":"Kantidakis T, Saponaro M, Mitter R, et al. Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev. 2016;30(4):408\u201320. https:\/\/doi.org\/10.1101\/gad.275453.115.","journal-title":"Genes Dev"},{"issue":"1","key":"1297_CR135","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2016.175","volume":"31","author":"A Bouska","year":"2017","unstructured":"Bouska A, Zhang W, Gong Q, et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia. 2017;31(1):83\u201391. https:\/\/doi.org\/10.1038\/leu.2016.175.","journal-title":"Leukemia"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:44:57Z","timestamp":1744350297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01297-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}